SODIUM EDECRIN 50 MG — DIN 00268313
ETHACRYNIC ACID (ETHACRYNATE SODIUM) : 50 MG · BAUSCH HEALTH, CANADA INC. · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: DORMANT
What is SODIUM EDECRIN?
SODIUM EDECRIN 50 MG contains ETHACRYNIC ACID (ETHACRYNATE SODIUM) : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 00268313, held by BAUSCH HEALTH, CANADA INC., supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as dormant, status dated 22-Dec-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is SODIUM EDECRIN used for?
EDECRIN (ethacrynic acid) is especially useful in patients unresponsive to the commonly used diuretics. It has been found useful in the following conditions: Congestive Heart Failure, Acute Pulmonary Edema, Renal Edema (Nephrotic syndrome), Hepatic Cirrhosis with Ascites.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Etacrynic Acid in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Etacrynic Acid, across 6 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAUSCH HEALTH, CANADA INC. | 2 | 1 | EDECRIN, SODIUM EDECRIN | Sourceable in Canada |
| STERIMAX INC | 2 | 1 | ETHACRYNATE SODIUM, ETHACRYNATE SODIUM FOR INJECTION USP | Sourceable in Canada |
| ENDO PAR INNOVATION COMPANY, LLC | 1 | 0 | ETHACRYNATE SODIUM FOR INJECTION | No marketed DIN |
| MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | 1 | 0 | EDECRIN TAB 50MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 50 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Available in high density polyethylene bottles of 100 tablets. |
| Storage | Store in tightly closed container at room temperature (15 °C - 30 °C). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Etacrynic Acid |
|---|---|
| ATC code | C03CC01 |
| AHFS class | 40:28.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00268313 |
|---|---|
| DIN (unpadded, as printed on some documents) | 268313 |
| Brand name | SODIUM EDECRIN |
| Generic / active ingredient | ETHACRYNIC ACID (ETHACRYNATE SODIUM) : 50 MG |
| Market authorization holder | BAUSCH HEALTH, CANADA INC. |
| Health Canada schedule | Prescription |
| ATC code | C03CC01 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C03CC |
| Current status | DORMANT |
| Status date | 22-Dec-2020 |
| Original market date | 1968-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 6 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| EDECRIN | 25 MG | TABLET | BAUSCH HEALTH, CANADA INC. | MARKETED | 02258528 |
| ETHACRYNATE SODIUM | 50 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02462362 |
| EDECRIN TAB 50MG | 50 MG | TABLET | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | 00016497 |
| ETHACRYNATE SODIUM FOR INJECTION | 50 MG | POWDER FOR SOLUTION | ENDO PAR INNOVATION COMPANY, LLC | CANCELLED PRE MARKET | 02479591 |
| ETHACRYNATE SODIUM FOR INJECTION USP | 50 MG | POWDER FOR SOLUTION | STERIMAX INC | DORMANT | 02469456 |
2 · Same class — other molecules in ATC C03CC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Etacrynic Acid | EDECRIN · EDECRIN TAB 50MG · ETHACRYNATE SODIUM · ETHACRYNATE SODIUM FOR INJECTION · +2 more | 6 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C03C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C03CA | Bumetanide · Furosemide · Torasemide | 81 | 23 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.